Maret is a privately held company engaged in the development and commercialization of small peptides to assist the body to recover from insult and injury. Clinical and pre-clinical research is currently being performed in the area of hematopoietic factors for cancer, immune system recovery and end stage renal disease (ESRD). The Company’s products in development are based on the activities of a family of small peptides related to the naturally occurring hormone Angiotensin.

Maret has completed a phase I/II clinical study to assess safety and preliminary efficacy of its lead peptide, MARstem™ on blood cell recovery in breast cancer chemotherapy patients.The early clinical results were presented at the International Symposium on New Drugs in Cancer Therapy in Amsterdam on November 10, 2000 (see Press Releases).

A phase II trial is underway to determine MARstem’s effect on anemia in end-stage renal disease (ESRD) patients and a new study will commence soon to assess MARstem’s ability to correct or prevent thrombocytopenia and leukopenia.
The Company is currently seeking partners to license and co-develop the hematopoiesis products.

Maret Corporation
4041 Macarthur Boulevard, Suite 375
Newport Beach, California  92660

Telephone : 949-225-0005
Fax : 949-225-0006
For Company Information: maret@maretpharma.com